Granulocytes as effective anticancer agent in experimental solid tumor models

Jaganjac, Morana; Poljak‐Blaži, Marija; Kirac, Iva; Borović, Suzana; Schaur, R. J.; Žarković, Neven

doi:10.1016/j.imbio.2010.01.002

Cited by 27 publications

(27 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, granulocytes have well-documented anticancer activity, with e.g., the administration of granulocytes reducing solid tumor growth and improving overall survival of tumor-bearing mice and rats. 13 Further, granulocytes are important anti-cancer immune effector cells in carcinoma, lymphoma and melanoma, 14,15 and are required for clinical activity of bladder cancer immunotherapy. 16 The most important function of granulocytes is that of phagocytosis of target cells.…”

Section: Discussionmentioning

confidence: 99%

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

Wiersma

Bruyn

Shi

et al. 2015

mAbs

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

Wiersma

Bruyn

Shi

et al. 2015

mAbs

View full text Add to dashboard Cite

show abstract

“…To study the role of immune modulators during tumour progression or regression 18 animals were injected intramuscularly in the right hindlimb with 250 µl of RPMI‐1640 medium containing 10 7 W256 tumour cells harvested from Wistar W256‐bearing donors. Nine animals were injected additionally with Sephadex (Sephadex G‐150; Pharmacia Fine Chemicals, Sweden), which abolishes spontaneous W256 tumour regression in Sprague–Dawley rats, into the right hindlimb [3,4]. The Sephadex was prepared and used as described elsewhere [6].…”

Section: Methodsmentioning

confidence: 99%

“…On days 4 and 7 after W256 injection, blood was taken from the tail vein in EDTA‐containing tubes for the differential counting of leucocytes and for plasma preparation [4]. Three healthy rats served as controls in all analyses.…”

Section: Methodsmentioning

confidence: 99%

“…A commercial rat 4‐plex luminex kit (R&D Systems, Minneapolis, MN, USA) was used for determination of CINC‐2, VEGF, IL‐6 and TNF‐α. The assay was performed as described previously [4], and plasma samples were diluted threefold according to the manufacturer's instructions. The assay was performed on a luminex‐200™ instrument using AtheNA Analyzer LX200 (full) 2·3 software.…”

Section: Methodsmentioning

confidence: 99%

“…Recently, it was reported that spontaneous regression/complete resistance to tumour cells is mediated by rapid infiltration of leucocytes, mainly as a consequence of innate immune response [2,3]. In addition, the administration of granulocytes at the site of solid tumours can lead to tumour regression or can slower tumour growth and extend the overall survival of animals [4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression

Jaganjac

Poljak‐Blaži

Schaur

et al. 2012

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe involvement of granulocytes in immune response against cancer is not well understood. Depending on the cytokine milieu in which they act and on their oxidative burst, granulocytes may play either an inhibitory or stimulatory role in tumour growth. Unsaturated fatty acids, essential components of cellular membranes and storage lipids, are susceptible to granulocyte-derived reactive oxygen species (ROS). ROS can induce lipid peroxidation (LPO) resulting in the destruction of biomembranes. Thus, murine W256 tumour progressing and tumour regressing animal models were used to study the involvement of plasma inflammatory mediators and oxidative burst of circulating granulocytes in malignant destruction and detrimental tumour growth. The involvement of LPO-derived aldehydes (i.e. acrolein, 4-hydroxy-2-nonenal and malondialdehyde) and myeloperoxidase (MPO) appearance in the granulocyte anti-cancer response were further evaluated. The results obtained revealed a significant increase in neutrophil elastase in animals with regressing tumour. Furthermore, the presence of MPO in tumour microenvironment was accompanied by the formation of acrolein only 5 h after tumour transplantation and its presence increased during tumour regression. Later, at an early stage of tumour regression, the presence of other LPO-derived aldehydes were also observed. The results obtained suggest that elevated neutrophil elastase and initiation of LPO may play an important role in the tumour development leading to tumour regression.

show abstract

Engineering and Targeting Neutrophils for Cancer Therapy

Zhang,

Gu,

Wang

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Neutrophils are the most abundant white blood cells in the circulation and act as the first line of defense against infections. Increasing evidence suggests that neutrophils possess heterogeneous phenotypes and functional plasticity in human health and diseases, including cancer. Neutrophils play multifaceted roles in cancer development and progression, and an N1/N2 paradigm of neutrophils in cancer has been proposed, where N1 neutrophils exert anti‐tumor properties while N2 neutrophils display tumor‐supportive and immune‐suppressive functions. Selective activation of beneficial neutrophil population and targeted inhibition or re‐polarization of tumor‐promoting neutrophils has shown an important potential in tumor therapy. In addition, due to the natural inflammation‐responsive and physical barrier‐crossing abilities, neutrophils and their derivatives (membranes and extracellular vesicles) are regarded as advanced drug delivery carriers for enhanced tumor targeting and improved therapeutic efficacy. In this review, we comprehensively presented the recent advances in engineering neutrophils for drug delivery and targeting neutrophils for remodeling tumor microenvironment. This review will provide a broad understanding of the potential of neutrophils in cancer therapy.This article is protected by copyright. All rights reserved

show abstract

Granulocytes as effective anticancer agent in experimental solid tumor models

Cited by 27 publications

References 17 publications

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression

Engineering and Targeting Neutrophils for Cancer Therapy

Contact Info

Product

Resources

About